Sorafenib is a multi-targeted, small molecule tyrosine kinase inhibitor that blocks proliferation of tumor cells by inhibiting RAF/MEK/ERK and other signaling pathways and inhibits VEGF and PDGF receptors to suppress tumor-related angiogenesis [12]. This evidence concerns the gene MAP2K7 and neoplasm.